GSK discloses good efficacy in psoriasis with GSK2856184

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
GSK discloses good efficacy in psoriasis with GSK2856184

MECHELEN, Belgium, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext: GLPG), a clinical stage biotech company focused on developing novel mode of action medicines, announces that GSK has disclosed on its website the Phase 2 psoriasis study results with selective JAK1 inhibitor GSK2856184, licensed from Galapagos.  The results show higher efficacy than those published for apremilast, a recently approved oral medicine for psoriasis and psoriatic arthritis.

GSK completed a multi-center study with GSK2586184 in 56 subjects with moderate to severe plaque-type psoriasis. In a double-blind and placebo controlled study in 13 centers in Germany and the United Kingdom, patients received either 100, 200, or 400 mg GSK2586184 BID, or placebo BID.  The treatment period was up to 12 weeks.  Each patient had 7 visits: baseline, at the start of treatment, after weeks 2, 4, and 8, at the end of treatment after 12 weeks, and a follow up at week 16. 

Efficacy results GSK2586184 versus apremilast:

Proportion of PASI 50, 75 and 90 responders at Week 12
 
    GSK2586184 BID   apremilast 1 BID
at Week 16
PASI Placebo
BID
100 mg 200 mg 400 mg   30 mg
PASI 50 0 %
(0/11)
29% (4/14) 36% (4/11) 69%
(9/13)
   
PASI 75 0 %
(0/11)
14% (2/14) 36% (4/11) 62%
(8/13)
  33% vs 5% placebo
PASI 90 0 %
(0/11)
0%
(0/14)
36% (4/11) 38%
(5/13)
   

In addition, GSK reported open label study data in 8 psoriasis patients which confirmed the double-blinded data above.

GSK reported the following safety results:

"No clinically important changes in clinical chemistry, hematology and urinalysis values were observed, with the exception of 1 severe thrombocytopenia event (reported as a severe adverse event).  In all GSK2586184 treatment groups, mean serum creatinine increased and remained elevated within the normal range (53-104.3 micro mol/L) throughout the study (highest mean increase of 12.5 micro mol/L).  Together with the absence of change in cystatin C and eGFR it seems likely that the creatinine elevations reflect the interaction of GSK2586184 with renal tubular transporters sMATE1 and MATE2-K, rather than functional impairment.  No changes in vital signs or ECGs were deemed clinically important."

"GSK2586184 is the second compound discovered by Galapagos to show good efficacy and safety, after selective JAK1 inhibitor GLPG0634 in rheumatoid arthritis.  GSK2586184 met the primary endpoint in psoriasis, with a PASI75 score of 62% vs placebo score of 0% at the 400 mg dose, with consistent PASI50 and PASI90 scores, and with a favorable safety profile in this study.  The reported efficacy scores are higher relative to those of apremilast, a recently approved oral therapy for psoriasis.  Galapagos expects that oral therapies and antibody therapies may have different applications and opportunities in the field of psoriasis," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.   

GSK has informed Galapagos that GSK2586184 will not be developed by GSK for oral administration in psoriasis due to the overall risk/benefit profile, including a drug-drug statin interaction liability.  GSK is evaluating other indications for development of GSK2586184.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a pipeline comprising three Phase 2 studies, two Phase 1 studies, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics and metabolic disease.  In the field of inflammation, AbbVie and Galapagos signed an agreement for the development and commercialization of GLPG0634 .  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease.  Galapagos has another selective JAK1 inhibitor, GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in 2012).  AbbVie and Galapagos signed an agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene.  Potentiator GLPG1837 is expected to start Phase 1 in 2014.  Galapagos also expects to nominate a pre-clinical candidate corrector before year end 2014.  The Galapagos Group, including fee-for-service subsidiary Fidelta, has around 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  Further information at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements

This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions.  Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

1 Source: Celgene website, press release dated March 2, 2013 containing Phase 3 study results.

HUG#1869160

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 24

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 44

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 9

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 220

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 20

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 236

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 131

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 84

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 43

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Gstar Accelerates Renewable Energy Production in Indonesia

Updated Category News Views 161

Gstar Accelerates Renewable Energy Production in Indonesia Gstar has achieved a significant milestone in its ambitious plans to establish a photovoltaic manufacturing hub in Indonesia. The company has successfully shipped the first batch of crucial equipment needed for this new facility. Included in this shipment are monocrystalline growth furnaces and advanced control...

Continue Reading
Western Pacific Trust Company Announces Annual Dividend Payout

Updated Category News Views 188

Western Pacific Trust Company Celebrates Dividend Announcement The announcement from Western Pacific Trust Company (TSXV: WP) brings exciting news for its shareholders. The company has declared its third consecutive annual dividend on common shares, reflecting its robust financial performance and steadfast dedication to shareholder value. This decision highlights WPTC’s...

Continue Reading
Virgin Galactic Unveils Exciting New Equity Selling Program

Updated Category News Views 164

Virgin Galactic Announces New At-The-Market Equity Program Virgin Galactic Holdings, Inc. (NYSE: SPCE) recently revealed an innovative sales initiative to enhance its capital through an at-the-market equity offering. This initiative allows the company to sell shares of its common stock, with an overall offering price reaching up to $300 million. This significant program...

Continue Reading
Carlisle Companies Inc (CSL) Achieves Record Stock Milestone

Updated Category News Views 97

Carlisle Companies Inc Reaches Historic Stock Performance Carlisle Companies Inc. (NYSE: CSL) has achieved an incredible milestone with its stock price soaring to $450.74, marking an all-time high. This remarkable achievement reflects the strong market performance and rising investor confidence in the company. Over the past year, Carlisle's stock has seen an impressive...

Continue Reading
Exploring the Expanding Epoxy Resins Market Dynamics Ahead

Updated Category News Views 199

The epoxy resin market was gearing up for some serious action, set to explode from USD 12.89 billion in 2023 to an impressive USD 20.85 billion by 2032. That’s a solid compound annual growth rate (CAGR) of 5.49% kicking off in 2024 and carrying right through the end of the decade. But hold on—what’s really fueling this surge? It ain't just luck; it’s a mix of...

Continue Reading